Drug Trial Radar · NCT01868997
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
Last checked: Nov 19, 2026Latest source record: Dec 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
88
Actual
Start
Jul 2013
Primary completion
Mar 2016
Study completion Feb 22, 2017
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jun 5, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to investigate the efficacy, safety, and tolerability of RV 001 (teprotumumab), a fully human anti-IGF1R antibody, administered q3W for 6 months, in comparison to placebo, in the treatment of participants suffering from active TED. "Funding Source - FDA OOPD"
Conditions
- Thyroid Associated Ophthalmopathies
- Thyroid-Associated Ophthalmopathy
Interventions
teprotumumabDrug
normal salineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Responder Status at Week 24Time frame: Week 24
Locations
15 sites in 4 countries. Site status is shown where the registry gives one.
Jules Stein Eye Institute at UCLA
Los Angeles, California
University of Denver
Aurora, Colorado
Emory University Department of Ophthalmology
Atlanta, Georgia
University of Iowa Hospitals and Clinics, Department of Ophthalmology
Iowa City, Iowa
Kellogg Eye Center at University of Michigan
Ann Arbor, Michigan
Washington University Department of Ophthalmology
St Louis, Missouri
University of Nebraska Medical Center Department of Ophthalmology
Omaha, Nebraska
Casey Eye Institute at Oregon Health and Science University
Portland, Oregon
Hamilton Eye Institute at University of Tennessee
Memphis, Tennessee
Eye Wellness Center
Houston, Texas
Medical College of Wisconsin, The Eye Institute
Milwaukee, Wisconsin
Johannes Gutenberg University Medical Center
Mainz, Germany
Fondazione Ca' Granda Ospedale Policlinico Graves GO Center
Milan, Italy
University of Pisa, Azienda Ospedaliera
Pisa, Italy
Moorfields Eye Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.